J&J picks top coronavirus vaccine candidate

06 April 2020


Johnson & Johnson has selected a lead vaccine candidate for the novel coronavirus and expects to start testing it in humans by September at the latest. That means J&J could disclose data before the end of the year, which then may allow the vaccine to be available for emergency use in early 2021, according to the pharma giant.

Relatedly, J&J also announced Monday an expanded partnership with the Biomedical Advanced Research and Development Authority, or BARDA. The parties have agreed to spend more than $1 billion to co-fund vaccine research, development and clinical testing.

Additionally, J&J said it will scale up its global vaccine manufacturing capacity so that more than a billion doses of a vaccine can be made. The company intends to soon start producing the vaccine “at risk,” and is “committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.”

Dive Insight:

J&J was the earliest big pharma to announce plans for developing a vaccine against the novel coronavirus, which causes the sometimes deadly respiratory illness COVID-19. J&J says it collaborated with academic institutions to produce what’s now J&J’s lead vaccine, as well as two back-up candidates.

Like other companies working on novel coronavirus vaccines, J&J is trying to speed up development. Vaccines typically take years to make and validate via testing, but the threats posed by a global pandemic are pushing drugmakers to move quicker.

BARDA is helping finance J&J’s vaccine work through an expanded agreement in which the agency funds development through Phase 1. After that early testing, BARDA can decide whether to invest more.

Along with vaccine work, J&J and BARDA have been screening libraries of chemical compounds in search of antivirals that could be used to treat this new virus. The libraries include J&J’s own, as well as those of other pharmaceutical companies. Notably, J&J has an infectious disease business that brings in more than $3 billion a year, most of which comes from five marketed antivirals used to treat HIV.

Antivirals, such as Gilead’s remdesivir, have garnered much attention as possible treatments for COVID-19. Yet there are other drug types under investigation too — Regeneron, Eli Lilly and Biogen, for example, are each investigating experimental antibodies.

Published by biopharmadive.com on March 30, 2020
Image from Shutterstock


Sign up

    Fill in your contact details to sign up for our newsletter.